

# HIV incidence and molecular characterization of new diagnoses in Argentina - a Global Fund project.

Pando, María de los Ángeles, Gómez Carrillo, Manuel, Vila, Marcelo, Rossi, Diana, Ralón, Gonzalo, Vignoles, Moira, Rubio, Andrea, Marone, Rubén, Reynaga, Elena, Sosa, Jorgelina, Torres, Oscar, Maestri, Miriam, Ávila, María Mercedes y Salomón, Horacio.

## Cita:

Pando, María de los Ángeles, Gómez Carrillo, Manuel, Vila, Marcelo, Rossi, Diana, Ralón, Gonzalo, Vignoles, Moira, Rubio, Andrea, Marone, Rubén, Reynaga, Elena, Sosa, Jorgelina, Torres, Oscar, Maestri, Miriam, Ávila, María Mercedes y Salomón, Horacio (Diciembre, 2009). *HIV incidence and molecular characterization of new diagnoses in Argentina - a Global Fund project. AIDS Vaccine 2009. Global HIV Vaccine Enterprise / Agence Nationale de Recherche sur le Sida et le hépatites virales, París, Francia.*

Dirección estable: <https://www.aacademica.org/gonzalo.ralon/25>

ARK: <https://n2t.net/ark:/13683/pcqZ/WUj>



Esta obra está bajo una licencia de Creative Commons.  
Para ver una copia de esta licencia, visite  
<https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es>.

Poster presentation

Open Access

## **P20-07. HIV incidence and molecular characterization of new diagnoses in Argentina. A global fund project**

M Pando\*<sup>1</sup>, M Gómez Carrillo<sup>1</sup>, M Vila<sup>2</sup>, D Rossi<sup>2</sup>, G Ralón<sup>2</sup>, M Vignoles<sup>1</sup>, AE Rubio<sup>1</sup>, R Marone<sup>3</sup>, E Reynaga<sup>4</sup>, J Sosa<sup>4</sup>, O Torres<sup>5</sup>, M Maestri<sup>5</sup>, MM Avila<sup>1</sup> and H Salomón<sup>1</sup>

Address: <sup>1</sup>Facultad de Medicina, Universidad de Buenos Aires, Centro Nacional de Referencia para el SIDA, Buenos Aires, Argentina, <sup>2</sup>Intercambios Asociación Civil, Buenos Aires, Argentina, <sup>3</sup>Nexo Asociación Civil, Buenos Aires, Argentina, <sup>4</sup>Asociación de Mujeres Meretrices de Argentina (AMMAR), Buenos Aires, Argentina and <sup>5</sup>Hospital Materno Infantil Ramón Sardá, Buenos Aires, Argentina

\* Corresponding author

from AIDS Vaccine 2009  
Paris, France. 19–22 October 2009

Published: 22 October 2009

*Retrovirology* 2009, **6**(Suppl 3):P377 doi:10.1186/1742-4690-6-S3-P377

This abstract is available from: <http://www.retrovirology.com/content/6/S3/P377>

© 2009 Pando et al; licensee BioMed Central Ltd.

### **Background**

The objective is to estimate HIV incidence and characterize subtypes among recently diagnosed individuals from different at-risk populations (men who have sex with men (MSM); female and male drug users (FDUs and MDUs); female, male and transvestite sex workers (FSWs, MSWs and TSWs)) and pregnant women (PW) from Argentina in the context of a Global Fund Project (Sub-project N° 112).

### **Methods**

From October 2006 to September 2008, HIV prevalence surveys were conducted among MSM, FDUs, MDUs, FSWs, MSWs, TSWs and PW. Volunteers older than 18 years old without previous HIV positive diagnosis were interviewed and tested for HIV. HIV positive samples were analyzed by the Serological Testing Algorithms for Recent HIV Seroconversion (STARHS) to estimate incidence. By partial RT-PCR and sequencing of HIV pol gene HIV subtype was determined.

### **Results**

A total of 12,200 volunteers were recruited in the cross-sectional HIV prevalence surveys. HIV prevalence between self-reported HIV negative or unknown status was 10.4% (161/1549), 5.1% (24/473), 2.9% (7/241), 10.8% (12/111), 33.9% (38/112), 1.9% (21/1112) and 0.12% (10/8570) for MSM, MDUs, FDUs, MSWs, TSWs, FSWs and

PW, respectively. HIV incidence estimates by STARHS were 6.36, 1.62, 2.73, 6.08, 11.31, 0.62 and 0.05 per 100 person-years for MSM, MDUs, FDUs, MSWs, TSWs, FSWs and PW, respectively. Phylogenetic analysis showed that 122 (61.6%) samples were subtype B, 74 (37.4%) were inter-subtype BF recombinants and 2 (1.0%) were subtype C. In all groups, men had higher prevalence of subtype B.

### **Conclusion**

Given the high HIV prevalence and incidence found in this study, it is imperative to have a well documented molecular profile of the epidemics in these groups. The high incidences observed in most of them make them suitable for considering them as potential volunteers in vaccine trials.